FDA Approves Tasigna® For Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demonstrate Major Advance Over …
Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) 150 mg capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The effectiveness of Tasigna is based on major molecular response and cytogenetic response rates. The study is ongoing and further …
Singapore Jamu Postnatal Massage Testimony -http://www.OriginsJamuMassage.com